Navigation Links
Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/6/2008

SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIO CEO & Investor Conference on February 12, 2008 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. David A. Walsey, Arena's Director of Corporate Communications, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
2. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
3. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
4. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
5. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
7. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
8. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):New management methods extend blackberry season 2Roe of marine animals is best natural source of omega-3 2Hard To Treat Diseases 28HTDS 29 to Retire Regulation D 504 Offering 56205 1Hard To Treat Diseases 28HTDS 29 to Retire Regulation D 504 Offering 56205 2Hard To Treat Diseases 28HTDS 29 to Retire Regulation D 504 Offering 56205 3Aflac Incorporated To Present at the Keefe Bruyette 26 Woods 2009 Insurance Conference 56203 1Aflac Incorporated To Present at the Keefe Bruyette 26 Woods 2009 Insurance Conference 56203 2Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 1Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 2Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 3Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 4Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 5Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 6Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 7Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 8Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 9Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 10Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 11Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 12Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 13Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 14Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 15Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 16Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 17Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 18Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 19Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 20Reportlinker Adds Proteomics 3A Technologies and Global Markets Report 13844 21